Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Assets (2016 - 2025)

Historic Current Assets for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $101.6 million.

  • Anika Therapeutics' Current Assets fell 2535.96% to $101.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.6 million, marking a year-over-year decrease of 2535.96%. This contributed to the annual value of $113.7 million for FY2024, which is 3040.68% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Current Assets is $101.6 million, which was down 2535.96% from $99.3 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Current Assets registered a high of $177.8 million during Q2 2021, and its lowest value of $99.3 million during Q2 2025.
  • Its 5-year average for Current Assets is $150.3 million, with a median of $160.3 million in 2023.
  • As far as peak fluctuations go, Anika Therapeutics' Current Assets surged by 766.36% in 2021, and later crashed by 3592.45% in 2025.
  • Anika Therapeutics' Current Assets (Quarter) stood at $168.5 million in 2021, then grew by 0.6% to $169.5 million in 2022, then fell by 3.68% to $163.3 million in 2023, then crashed by 30.41% to $113.7 million in 2024, then decreased by 10.61% to $101.6 million in 2025.
  • Its Current Assets was $101.6 million in Q3 2025, compared to $99.3 million in Q2 2025 and $102.5 million in Q1 2025.